In addition, the present study, including the simultaneous assessment of PSA assessments and ctDNA, offers a significant opportunity to investigate prostate tumor dynamics thanks to a sequential monitoring of PSA during therapy as a surrogate biomarker of the emergence of resistance to treatment. The gene discussed is KLK3; the disease is prostate neoplasm.